Accent Capital Management’s Edwards Lifesciences EW Stock Holding History

Accent Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42	Closed	-$3.27K	–	357
2025 Q3	$3.27K	Hold	42	–	–	﹤0.01%	350
2025 Q2	$3.29K	Hold	42	–	–	﹤0.01%	363
2025 Q1	$3.04K	Buy	+42	New	+$3.01K	﹤0.01%	289
2024 Q1	–	Sell	-4,040	Closed	-$308K	–	173
2023 Q4	$308K	Buy	+4,040	New	+$281K	0.24%	51

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Accent Capital Management's EW Position: Q4 2025 in Review

Accent Capital Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 42 shares — an estimated $3.27K sold.

Accent Capital Management first reported a position in EW in Q4 2023 and held it in 4 quarters. The position peaked at $308K in Q4 2023. 1,315 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Accent Capital Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Accent Capital Management sold 42 Edwards Lifesciences shares in Q4 2025, an estimated $3.27K.
Accent Capital Management first reported a position in Edwards Lifesciences in Q4 2023 and held it in 4 quarters.
Accent Capital Management's Edwards Lifesciences position peaked at $308K in Q4 2023.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Accent Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.